Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Opus Genetics (IRD) Capital Expenditures (2020)

Opus Genetics has reported Capital Expenditures over the past 5 years, most recently at -$30154.0 for Q4 2020.

Quarterly Capital Expenditures changed N/A to -$30154.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $33844.0 through Sep 2014, down 27.15% year-over-year, with the annual reading at $25000.0 for FY2019, 36.26% down from the prior year.
Capital Expenditures was -$30154.0 for Q4 2020 at Opus Genetics, down from $15940.0 in the prior quarter.
Over five years, Capital Expenditures peaked at -$30154.0 in Q4 2020 and troughed at -$30154.0 in Q4 2020.